Cost-effectiveness analyses of amivantamab plus lazertinib and lazertinib versus osimertinib in non-small cell lung cancer with EGFR mutations

Cost-effectiveness analyses of amivantamab plus lazertinib and lazertinib versus osimertinib in non-small cell lung cancer with EGFR mutations

BackgroundThe combination of amivantamab and lazertinib has demonstrated clinically significant and sustained antitumor effects in both treatment-naïve and osimertinib-pretreated advanced non-small cell lung cancer (NSCLC) patients harboring previously untreated epidermal growth factor receptor (EGF...

Full description

Saved in:
Bibliographic Details
Main Authors: Hui Zhang, Yueyun Li, Yuhang Liu, Haonan Li, Hong Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Pharmacology
Subjects:
amivantamab
lazertinib
osimertinib
cost-effectiveness analysis
non-small cell lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1527614/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items